ACXP Stock Price, Acurx Pharmaceuticals, . Quote, Chart

Market Summary

USD2.27+0.11

Delayed

5.09%

ACXP Stock Price

View Fullscreen

ACXP RSI Chart

ACXP Valuation

Market Cap

36.0M

Price/Earnings (Trailing)

-2.24

Price/Free Cashflow

-3.29

ACXP Price/Earnings (Trailing)

ACXP Profitability

Return on Equity

-267.61%

Return on Assets

-176.23%

Free Cashflow Yield

-30.39%

ACXP Fundamentals

ACXP Earnings

Earnings (TTM)

-16.1M

Earnings Growth (Yr)

-50.81%

Earnings Growth (Qtr)

14.4%

Breaking Down ACXP Revenue

Last 7 days

11.8%

Last 30 days

26.1%

Last 90 days

-29.5%

Trailing 12 Months

-24.6%

How does ACXP drawdown profile look like?

ACXP Financial Health

Current Ratio

2.3

ACXP Investor Care

Shares Dilution (1Y)

35.74%

Diluted EPS (TTM)

-1.18

Tracking the Latest Insider Buys and Sells of Acurx Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 19, 2024	sailer carl	acquired	70,066	3.55	19,737	-
Jan 03, 2024	deluccia robert j	acquired	70,066	3.55	19,737	-
Jan 03, 2024	luci david p	acquired	70,066	3.55	19,737	president and ceo
Dec 22, 2023	deluccia robert j	gifted	-	-	-30,000	-
Dec 12, 2023	deluccia robert j	gifted	-	-	-40,000	-
Jul 27, 2022	deluccia robert j	bought	75,000	3.8	19,737	-
Jul 27, 2022	luci david p	bought	75,000	3.8	19,737	president and ceo
Jul 27, 2022	sailer carl	bought	75,000	3.8	19,737	-
Dec 02, 2021	deluccia robert j	gifted	-	-	-40,000	-
Nov 23, 2021	sailer carl	bought	24,979	4.84	5,161	-

Which funds bought or sold ACXP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Semmax Financial Advisors Inc.	unchanged	-	-4,173	12,287	-%
May 15, 2024	Royal Bank of Canada	reduced	-30.19	-	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	31,816	31,816	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	7,027	7,027	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-54.00	-	-%
May 15, 2024	MORGAN STANLEY	added	62.96	2,632	64,682	-%
May 15, 2024	STATE STREET CORP	added	52.16	-2,916	106,492	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-23,671	42,025	-%
May 13, 2024	XTX Topco Ltd	new	-	31,950	31,950	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	3.76	-144,422	285,105	-%

Are Funds Buying or Selling ACXP?

Are funds buying ACXP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACXP

No. of Funds

Unveiling Acurx Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	723,104	SC 13G/A
Feb 14, 2023	armistice capital, llc	7.59%	880,000	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	2,997,111	SC 13G

Recent SEC filings of Acurx Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 17, 2024	RW	RW
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	FWP	Prospectus Filed

Peers (Alternatives to Acurx Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Acurx Pharmaceuticals, Inc. News

Latest updates

Acurx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	18.2%	9,109	7,709	8,126	8,543	8,960	9,377	9,259	11,322	13,254	14,990	17,440	3,224
Current Assets	-	-	-	7,158	9,236	7,385	9,377	9,209	-	13,254	-	-	-
Cash Equivalents	19.4%	8,921	7,474	7,052	9,146	7,179	9,112	9,092	11,083	12,959	14,459	17,096	3,175
Liabilities	2.2%	3,110	3,042	3,223	3,019	2,074	2,062	474	633	844	712	1,919	522
Current Liabilities	2.2%	3,110	3,042	3,223	3,019	2,074	2,062	474	633	844	712	1,919	473
Shareholder's Equity	28.5%	5,999	4,667	3,935	6,216	5,311	7,315	8,785	10,689	12,410	14,277	15,522	2,702
Retained Earnings	-8.2%	-57,596	-53,218	-48,104	-44,989	-41,544	-38,641	-31,838	-29,218	-26,548	-23,921	-19,279	-13,800
Additional Paid-In Capital	9.9%	63,580	57,871	52,026	51,193	46,844	45,944	40,614	39,897	38,948	38,188	34,791	-
Shares Outstanding	8.9%	15,757	14,468	13,005	13,005	11,672	11,628	10,263	10,233	10,216	10,116	6,908	-
Float	-	-	-	-	27,900	-	-	29,800	-	-	-	48,100	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	27.0%	-3,062	-4,197	-2,093	-1,576	-1,932	-1,495	-2,180	-1,990	-1,876	-1,500	-2,636	-329	-547	-	-	-
Share Based Compensation	7.3%	895	833	833	806	733	697	697	717	761	673	2,071	2,220	192	-	-	-
Cashflow From Financing	-2.4%	4,510	4,620	-	-	-	-1*	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACXP Income Statement

2024-03-31

CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
OPERATING EXPENSES
Research and Development	$ 1,555,011	$ 1,015,583
General and Administrative	2,822,878	1,887,374
TOTAL OPERATING EXPENSES	4,377,889	2,902,957
NET LOSS	$ (4,377,889)	$ (2,902,957)
LOSS PER SHARE
Basic net loss per common share	$ (0.28)	$ (0.25)
Diluted net loss per common share	$ (0.28)	$ (0.25)
Weighted average common shares outstanding basic	15,472,507	11,639,395
Weighted average common shares outstanding diluted	15,472,507	11,639,395

ACXP Balance Sheet

2024-03-31

CONDENSED INTERIM BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash	$ 8,920,926	$ 7,474,188
Other Receivable		129,159
Prepaid Expenses	187,908	105,776
TOTAL ASSETS	9,108,834	7,709,123
CURRENT LIABILITIES
Accounts Payable and Accrued Expenses	3,110,242	3,042,438
TOTAL CURRENT LIABILITIES	3,110,242	3,042,438
TOTAL LIABILITIES	3,110,242	3,042,438
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Common Stock; $.001 par value, 200,000,000 shares authorized, 15,757,102 and 14,468,229 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	15,757	14,468
Additional Paid-In Capital	63,579,577	57,871,070
Accumulated Deficit	(57,596,742)	(53,218,853)
TOTAL SHAREHOLDERS' EQUITY	5,998,592	4,666,685
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 9,108,834	$ 7,709,123

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

CEO	Mr. David P. Luci CPA, CPA, Esq., J.D.
WEBSITE	acurxpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Acurx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Acurx Pharmaceuticals, Inc.? What does ACXP stand for in stocks?

ACXP is the stock ticker symbol of Acurx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acurx Pharmaceuticals, Inc. (ACXP)?

As of Fri May 17 2024, market cap of Acurx Pharmaceuticals, Inc. is 35.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACXP stock?

You can check ACXP's fair value in chart for subscribers.

What is the fair value of ACXP stock?

You can check ACXP's fair value in chart for subscribers. The fair value of Acurx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acurx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acurx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACXP is over valued or under valued. Whether Acurx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acurx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACXP.